HR 3453 108th Congress House

RU-486 Suspension and Review Act of 2003

Official title: To provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug commonly known as RU-486 is deemed to have been withdrawn,… Show full official titleShow less

Official title: To provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug commonly known as RU-486 is deemed to have been withdrawn, to provide for the review by the Comptroller General of the United States of the process by which the Food and Drug Administration approved such drug, and for other purposes.

Introduced: November 6, 2003 See on congress.gov

Health AbortionAdministrative procedureCommerceCongress

More subjectsShow fewer subjects

Congressional investigationsCongressional reporting requirementsCongressional vetoDepartment of Health and Human ServicesDrug approvalsDrugsFood and Drug Administration (FDA)Government Operations and PoliticsGovernment publicityLabelingLaw

Everywhere this bill has been 3 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Nov 14, 2003

Referred to the Subcommittee on Health.

Nov 6, 2003

Referred to the House Committee on Energy and Commerce.

Nov 6, 2003

Introduced in House

Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

Latest action November 14, 2003

Referred to the Subcommittee on Health.

Plain-English summary Congressional Research Service

RU-486 Suspension and Review Act of 2003 - Deems the approved application for the drug mifepristone (marketed as Mifeprex, commonly known as RU-486, and used for the chemically induced termination of intrauterine pregnancy) to have been suspended.

Directs the Comptroller General to review and report on the process by which the Food and Drug Administration (FDA) approved mifepristone. Provides for the contingent reinstatement of such drug if the report determines the approval to have been in accordance with the Federal Food, Drug, and Cosmetic Act.

Related & companion bills 1

Bill text 1 version

Introduced in House Formatted Text PDF

Source documents hosted by congress.gov.

Committees of jurisdiction 2

Energy and Commerce Committee
House of Representatives
Health Subcommittee
House of Representatives · subcommittee of Energy and Commerce Committee

Cosponsors 22

Sessions, Pete

Texas · Mar 16, 2004

Rogers, Harold

Kentucky · Mar 11, 2004

Mississippi · Nov 21, 2003

Blackburn, Marsha

Tennessee · Nov 18, 2003

Aderholt, Robert B.

Alabama · Nov 6, 2003

Boozman, John

Arkansas · Nov 6, 2003

Oklahoma · Nov 6, 2003

Smith, Christopher H.

New Jersey · Nov 6, 2003

South Carolina · Nov 6, 2003

Cite this page click to expand

APA

U.S. Congress. (2026). H.R. 3453: RU-486 Suspension and Review Act of 2003. 108th Congress. Open America. https://openamerica.io/bill/108-HR-3453/

MLA

"H.R. 3453: RU-486 Suspension and Review Act of 2003." 108th Congress, 2026, Open America, https://openamerica.io/bill/108-HR-3453/.

Bluebook (legal)

H.R. 3453, 108th Cong. (2026), https://openamerica.io/bill/108-HR-3453/.

Markdown link

[H.R. 3453: RU-486 Suspension and Review Act of 2003](https://openamerica.io/bill/108-HR-3453/)